| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, N12W6, Sapporo, Hokkaido 060, Japan
To assess whether CYP3A4 and CYP3A7 have a similar capacity to activate carcinogenic mycotoxins, we established cell lines stably expressing human CYP3A4 and CYP3A7, which are adult- and fetal-specific forms of cytochrome P450 in human livers, respectively. Each cDNA was introduced into CR-119 cells which had been established by introducing guinea pig NADPH-cytochrome P450 reductase cDNA into Chinese hamster lung cells. The cell lines (4-line and 7-line) stably expressed the mRNA and the protein corresponding to CYP3A4 and CYP3A7, respectively. The concentration-response for aflatoxin B1 (AFB1) cytotoxicity in 4-line and 7-line, respectively, was compared. 410 and 740 cells were approximately 17- and 20 times more sensitive to AFB1 than the parental CR-119 cells, respectively. In addition, the sensitivities to AFB1 of both 410 and 740 cells were enhanced approximately seven times by the addition of 10 µM
-naphthoflavone, a known activator of CYP3A enzyme, while the sensitivities were suppressed approximately four times by the addition of 100 µM troleandomycin, which forms a metabolite intermediate complex with CYP3A enzyme. Moreover, both cell lines showed approximately 10 and 2 times higher sensitivity to sterigmatocystin and aflatoxin G1 than CR-119 cells, respectively. These results indicate that CYP3A4 and CYP3A7 have essentially similar capacities to activate AFB1, sterigmatocystin, and aflatoxin G1 to produce toxic metabolites.
1 This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan.
2 Present address: Division of Environmental Hygiene, Hokkaido Institute of Pharmaceutical Sciences, 7-1 Katsuraoka-cho, Otaru, Hokkaido 047-02, Japan.
3 Present address: Division of Bio-Medical and Immunology, Faculty of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565, Japan.
4 To whom requests for reprints should be addressed.
Received 10/ 4/94. Accepted 12/ 8/94.
This article has been cited by other articles:
![]() |
G. Ginsberg, D. Hattis, R. Miller, and B. Sonawane Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children Pediatrics, April 1, 2004; 113(4/S1): 973 - 983. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ariyoshi, S. Imaoka, K. Nakayama, Y. Takahashi, K.-I. Fujita, Y. Funae, and T. Kamataki Comparison of the Levels of Enzymes Involved in Drug Metabolism between Transgenic or Gene-knockout and the Parental Mice Toxicol Pathol, January 1, 2001; 29(1_suppl): 161 - 172. [Abstract] [PDF] |
||||
![]() |
N. Kondoh, T. Wakatsuki, A. Ryo, A. Hada, T. Aihara, S. Horiuchi, N. Goseki, O. Matsubara, K. Takenaka, M. Shichita, et al. Identification and Characterization of Genes Associated with Human Hepatocellular Carcinogenesis Cancer Res., October 1, 1999; 59(19): 4990 - 4996. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bylund, T. Kunz, K. Valmsen, and E. H. Oliw Cytochromes P450 with Bisallylic Hydroxylation Activity on Arachidonic and Linoleic Acids Studied with Human Recombinant Enzymes and with Human and Rat Liver Microsomes J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 51 - 60. [Abstract] [Full Text] |
||||
![]() |
T. Saito, Y. Takahashi, H. Hashimoto, and T. Kamataki Novel Transcriptional Regulation of the Human CYP3A7 Gene by Sp1 and Sp3 through Nuclear Factor kappa B-like Element J. Biol. Chem., October 5, 2001; 276(41): 38010 - 38022. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |